Imatinib mesylate reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukemia

2024-11-0920150006-4971N/Ahttps://hdl.handle.net/20.500.14288/8743HematologyImatinib mesylate reduces bone marrow fibrosis and overwhelms the adverse prognostic impact of reticulin formation in patients with chronic myeloid leukemiaMeeting Abstract1528-0020Q111963